Blueprint Medicines (BPMC) Misses Q4 EPS by 2c

Blueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($2.65), $0.02 worse than the analyst estimate of ($2.63). Revenue for the quarter came in at $38.78 million versus the consensus estimate of $34.16 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• Goldman sees India AI infrastructure stocks up 60% in 2026
• Forgent Power Solutions, Inc. (FPS) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY27 Guidance